Black Hairy Tongue Associated with Erlotinib Treatment in a Patient with Advanced Lung Cancer
Annals of Dermatology
;
: 526-528, 2011.
Article
in English
| WPRIM
| ID: wpr-29024
ABSTRACT
Erlotinib is a tyrosine kinase inhibitor that acts on the epidermal growth factor receptor (EGFR). There have been many reports of the mucocutaneous side effects related to several EGFR inhibitors (EGFRIs). However, no case of black hairy tongue (BHT) associated with EGFRI has been reported. Herein, we report the first case of erlotinib-induced BHT in a 61-year-old man with advanced lung cancer. Considering recent use of EGFRIs worldwide, dermatologists should recognize the possible occurrence of BHT associated with EGFRIs such as erlotinib.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Quinazolines
/
Tongue, Hairy
/
Protein-Tyrosine Kinases
/
Butylated Hydroxytoluene
/
ErbB Receptors
/
Erlotinib Hydrochloride
/
Lung
/
Lung Neoplasms
Limits:
Humans
Language:
English
Journal:
Annals of Dermatology
Year:
2011
Type:
Article
Similar
MEDLINE
...
LILACS
LIS